Search

A consortium led by the Spanish company OneChain Immunotherapeutics has received 1.9M euros from the Spanish Ministry of Science and Innovation to advance a groundbreaking therapy, based on CAR T

Biotechnology is providing answers to rare diseases in areas with unresolved clinical needs such as diagnosis and treatment, through advanced therapies, biomarkers, and the development of new

OneChain Immunotherapeutics (OCI), a clinical-stage biotechnology company focused on the development of CAR T therapies for the treatment of oncologic diseases, announced Stefanos Theoharis as the

ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic.

ProductLife Group, partner of the ET Health consortium, APNEAL project, as a regulatory figure and to accelerate patient access to innovative health technologies.

Vaxdyn leads the KLEBSIELLA research project against the antibiotic-resistant bacterium Klebsiella pneumoniae, which directly causes more than 650,000 deaths worldwide each year.

Alira Health experts explain in an interview the importance of involving patients with rare diseases in the evaluation process of a new healthcare technology.

Oryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today reported financial results for the fourth

EuropaBio, of which AseBio is a member, proposes five basic principles to achieve a competitive European industrial biotechnology sector in view of the publication of the Work Program for 2024

The awards recognized the work of Belén Diego, collaborator for Diariofarma and correspondent for APM Health Europe in Spain and Portugal, and Miguel Sanmartín, founder of Capital Radio and host of

BCN HEALTH has published the study "Incidence and medical costs of lupus in Spanish hospitals: a retrospective database analysis" in the Orphanet Journal of Rare Diseases, an international peer

Meet Cobiomic Biosciences, our new member. We talked to its Carlos Pérez Sánchez, fundador y director.

Nitrosamines represent a significant health risk, being potentially carcinogenic and a major concern in pharmaceutical manufacturing processes.

NN-8828 is a first-in-class monoclonal antibody in dermatology with high affinity for the cytokine IL-21 that has been developed by Novo Nordisk to Phase II in non-dermatological indications.

The Cluster Tecnolóxico Empresarial das Ciencias da Vida, who will be the captain of the initiative, presented said initiative in the SCIEB of the Biopolo Sionlla in which 12 other entities Porguguese